In this issue:
Prognostic methylation markers for AML
Outcomes in double-hit lymphoma
KIR3DL1/HLA-B subtypes govern AML relapse after HCT
Pembrolizumab for R/R classic Hodgkin lymphoma
AlloSCT after azacitidine bridge in MDS and AML
Pembrolizumab in CLL and Richter transformation or relapsed CLL
Bendamustine for previously treated NHL
Cessation of nilotinib in chronic phase CML
EGR2 mutations define a new subgroup of CLL
De-escalation of TKI dose in CML
Please login below to download this issue (PDF)